TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35129242

Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX; n = 55)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Treatment as usual (TAU; n = 59)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: HIV clinic‐based extended‐release naltrexone (XR‐NTX) among those initiating medication
Number of subjects: 114

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) among those initiating medication
Number of subjects: 114
Study: 34486272

Group type: EXPERIMENTAL
Intervention: Lactoginal vaginal probiotic after standard antibacterial therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard antibacterial therapy
Number of subjects: 120
Study: 32273244

Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention (3 weekly sessions lasting 90 to 120 minutes)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sleep improvement intervention
Number of subjects: 120
Study: 35627446

Group type: EXPERIMENTAL
Intervention: High-low impact aerobics program supplemented by one EMG biofeedback session and pelvic floor muscle training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 34081045

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 24
Study: 32847917

Group type: EXPERIMENTAL
Intervention: Xueshuantong injection (lyophilised) (XST)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: 1/20th dose of Xueshuantong injection (lyophilised) (Control)
Number of subjects: 1200
Study: 35252270

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 369

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 369
Study: 32444250

Group type: EXPERIMENTAL
Intervention: Azathioprine 2.5 mg/kg/day with oral curcumin 3 g/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 34432204

Group type: EXPERIMENTAL
Intervention: Kangfuyan Capsules (4 capsules, 3 times daily for 12 weeks)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Gongyanping Capsules (control group, 4 capsules, 3 times daily for 12 weeks)
Number of subjects: 240
Study: 36361252

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 33187506

Group type: EXPERIMENTAL
Intervention: Immediate advance care plan group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Deferred advance care plan group
Number of subjects: 36
Study: 33966118

Group type: EXPERIMENTAL
Intervention: metreleptin treatment
Number of subjects: 1
Study: 32723072

Group type: EXPERIMENTAL
Intervention: Mobile health intervention with automated assessment and behavior change calls for patients and structured feedback for caregivers.
Number of subjects: 0
Study: 32581041

Group type: EXPERIMENTAL
Intervention: Camrelizumab
Number of subjects: 1

Group type: COMPARATOR
Intervention: Cisplatin and docetaxel (first-line treatment)
Number of subjects: 1
Study: 36459262

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging incubator (TLI) (EmbryoScope)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard incubators (SI, G185 K-System)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging incubator (TLI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard incubators (SI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both TLI and SI
Number of subjects: 9
Study: 33714741

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4725

Group type: COMPARATOR
Intervention: High burden of HF signs and symptoms (?3)
Number of subjects: 4725

Group type: COMPARATOR
Intervention: Orthopnea
Number of subjects: 4725

Group type: COMPARATOR
Intervention: Rales
Number of subjects: 4725
Study: 36154603

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg tablet 90 minutes before surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Clonidine 150 µg tablet 90 minutes before surgery
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 92
Study: 34077619

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) applied via microneedling
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo applied via microneedling
Number of subjects: 20
Study: 32982212

Group type: EXPERIMENTAL
Intervention: Ensifentrine 0.75 to 6mg twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ensifentrine 6mg
Number of subjects: 100
Study: 35387855

Group type: EXPERIMENTAL
Intervention: In-person HOBSCOTCH (H-IP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Virtual HOBSCOTCH (H-V)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 85
Study: 33120137

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (N = 67)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Mindfulness-based stress reduction group therapy (N = 58)
Number of subjects: 125
Study: 36072375

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) exercise for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brisk walking (BW) exercise for 48 weeks
Number of subjects: 0
Study: 34315475

Group type: EXPERIMENTAL
Intervention: Seasonal malaria chemoprevention (SMC) with azithromycin (AZ)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Seasonal malaria chemoprevention (SMC)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Seasonal malaria chemoprevention (SMC) and SMC + AZ
Number of subjects: 636
Study: 34801002

Group type: EXPERIMENTAL
Intervention: body image chatbot
Number of subjects: 2800

Group type: COMPARATOR
Intervention: assessment-only control condition
Number of subjects: 2800
Study: 36327169

Group type: EXPERIMENTAL
Intervention: Low-dose alfaxalone (LDA) 2 mg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose alfaxalone (HDA) 5 mg/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 10
Study: 35621299

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (20 mg from day 1 of the menstrual cycle till trigger day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone antagonist (Cetrorelix 0.25 mg s/c from the day leading follicle reached 14 mm until trigger day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone antagonist
Number of subjects: 100
Study: 32978021

Group type: EXPERIMENTAL
Intervention: Experimental patellae with 1 enlarged drill hole (12 mm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental patellae with 2 enlarged drill holes (12 mm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental patellae with 3 enlarged drill holes (12 mm)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control patellae
Number of subjects: 60
Study: 32450979

Group type: EXPERIMENTAL
Intervention: Visual Inspection (VIS)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Radiographic Examination (RAD)
Number of subjects: 252
Study: 36204961

Group type: EXPERIMENTAL
Intervention: All-ceramic onlay restoration (n=48)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Full crown restoration (Control group, n=47)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study: 33962129

Group type: EXPERIMENTAL
Intervention: TEACCH training plus Discrete Trial Teaching (DTT) for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: DTT only
Number of subjects: 60
Study: 32584674

Group type: EXPERIMENTAL
Intervention: Rituximab for FDA-approved indications
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: Rituximab for off-label use
Number of subjects: 1674

Group type: EXPERIMENTAL
Intervention: Factors associated with FDA-approved indication
Number of subjects: 1674
Study: 35222900

Group type: EXPERIMENTAL
Intervention: Acupoint injection of mecobalamin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional stroke treatment and nursing
Number of subjects: 60
Study: 34872568

Group type: EXPERIMENTAL
Intervention: Dienogest (DNG)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gonadotropin‐releasing hormone agonist (GnRHa)
Number of subjects: 49
Study: 32732305

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 634

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 634
Study: 36167066

Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: SpeechVive
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 34154628

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment group (balloon group, n = 38)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) treatment group (stent group, n = 42)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment group (balloon group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES) treatment group (stent group)
Number of subjects: 80
Study: 32233633

Group type: EXPERIMENTAL
Intervention: KAP-based rehabilitation education
Number of subjects: 70
Study: 34551782

Group type: EXPERIMENTAL
Intervention: EIT‐4‐BPSD implementation strategy
Number of subjects: 93
Study: 32090404

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study: 36123638

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking (UCM)
Number of subjects: 200
Study: 34029338

Group type: EXPERIMENTAL
Intervention: 1-way SMS messaging
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: 2-way SMS messaging
Number of subjects: 824

Group type: COMPARATOR
Intervention: Control (no SMS messaging)
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 824
Study: 32777104

Group type: COMPARATOR
Intervention: 400 IU
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 4000 IU
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 10,000 IU
Number of subjects: 311
Study: 35092484

Group type: EXPERIMENTAL
Intervention: 6-week MBSR (n=26)
Number of subjects: 51
Study: 34639353

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham condition
Number of subjects: 30
Study: 34294068

Group type: EXPERIMENTAL
Intervention: Palliative Care Needs Rounds
Number of subjects: 21
Study: 34889832

Group type: EXPERIMENTAL
Intervention: Cost-informed group (53% of participants)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cost-blind group (47% of participants)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Cost-blind group (after receiving cost information)
Number of subjects: 127
Study: 33007112

Group type: EXPERIMENTAL
Intervention: DensNet121 with transfer learning
Number of subjects: 112120

Group type: EXPERIMENTAL
Intervention: CNN and radiomics-based methods
Number of subjects: 112120

Group type: EXPERIMENTAL
Intervention: Transfer learning with good dataset selection, dropout, cycling learning rate, freezing/unfreezing layers
Number of subjects: 112120

Group type: EXPERIMENTAL
Intervention: Transfer learning with > 35,000 images
Number of subjects: 112120

Group type: EXPERIMENTAL
Intervention: Transfer learning using X-ray images from the same anatomical site
Number of subjects: 112120

Group type: EXPERIMENTAL
Intervention: Transfer learning using pretrained networks from ImageNet
Number of subjects: 112120
Study: 35069956

Group type: EXPERIMENTAL
Intervention: Hyperbaric ropivacaine 15 mg (Group R)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 15 mg with intrathecal fentanyl 20 μg (Group RF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (Group R and Group RF)
Number of subjects: 50
Study: 32838678

Group type: EXPERIMENTAL
Intervention: Adapted School Mental Health Program (SMHP)
Number of subjects: 960
Study: 35861630

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily for 104 weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo once daily for 104 weeks
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Canagliflozin and Placebo
Number of subjects: 308
Study: 34284154

Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducational program (EG)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 296
Study: 35779894

Group type: EXPERIMENTAL
Intervention: Teherán‐Morales's color grading scale
Number of subjects: 150

Group type: COMPARATOR
Intervention: Subjective assessment by experts
Number of subjects: 150
Study: 35928886

Group type: EXPERIMENTAL
Intervention: Late afternoon endurance exercise
Number of subjects: 12
Study: 34865095

Group type: EXPERIMENTAL
Intervention: Local oxygen-ozone therapy plus medical treatment (n=13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Medical treatment only (Control group, n=12)
Number of subjects: 25
Study: 32705692

Group type: EXPERIMENTAL
Intervention: Single dose oral rifampin (RIF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Renal impairment (RI)
Number of subjects: 0
Study: 33121523

Group type: EXPERIMENTAL
Intervention: Endovascular or surgical management
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Innovative treatments
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 1212
Study: 34893397

Group type: EXPERIMENTAL
Intervention: Backboard
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 32054287

Group type: EXPERIMENTAL
Intervention: Intervention schools (Sun Safe Schools intervention)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 118
Study: 32504611

Group type: EXPERIMENTAL
Intervention: Tweeted articles
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Randomization to tweeting
Number of subjects: 112
Study: 33940662

Group type: EXPERIMENTAL
Intervention: Desensibilize KF with potassium nitrate and 0.2% sodium fluoride (PN)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxa-Gel with potassium oxalate (PO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study: 33778994

Group type: EXPERIMENTAL
Intervention: Peer support groups (engaging in income generation, table banking, addressing food security, financial and moral support)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peer support groups (monthly for the first two months, then every three months for the remainder of the year)
Number of subjects: 20
Study: 36269852

Group type: EXPERIMENTAL
Intervention: Ivermectin, 400 μg/kg, daily for 3 days (n=817)
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Placebo (n=774)
Number of subjects: 1591
Study: 34315237

Group type: EXPERIMENTAL
Intervention: Genetically predicted insomnia
Number of subjects: 0
Study: 33897216

Group type: EXPERIMENTAL
Intervention: Educational plan based on Roy adaptation model, delivered through face-to-face and group training program in 6 sessions over one month, followed by a 4-week follow-up period.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 60
Study: 35668348

Group type: EXPERIMENTAL
Intervention: CACB+IPACK
Number of subjects: 0

Group type: COMPARATOR
Intervention: CACB+SHAM
Number of subjects: 0
Study: 32746899

Group type: EXPERIMENTAL
Intervention: Tonic conventional stimulation (TCS)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Burst stimulation (BURST)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (HF)
Number of subjects: 28
Study: 33301188

Group type: EXPERIMENTAL
Intervention: Inoculation with Thiobacillus sp.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inoculation with Funneliformis mosseae
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inoculation with Funneliformis mosseae + Thiobacillus sp.
Number of subjects: 3

Group type: COMPARATOR
Intervention: No-inoculation
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control (0.91 dS/m)
Number of subjects: 3
Study: 34057752

Group type: EXPERIMENTAL
Intervention: Postoperative 3D-computed tomography (CT) and gait analysis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinematic pelvic changes during gait
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinematic pelvic changes
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative cup position
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Factors correlating with pelvic mobility
Number of subjects: 60
Study: 32628676

Group type: EXPERIMENTAL
Intervention: Proteome‐by‐phenome Mendelian Randomization (MR) using 64 replicated locally‐acting variants as instrumental variables
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Proteome‐by‐phenome MR
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Causal role of tyrosine‐protein phosphatase non‐receptor type substrate 1 (SHPS1; SIRPA)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Intestinal fatty acid binding protein (FABP2) abundance
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Causal role of four proteins (FGF5, IL6R, LPL, LTA)
Number of subjects: 509
Study: 35157370

Group type: EXPERIMENTAL
Intervention: GDC-0214 (15 mg twice daily for 14 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 99mTc-radiolabeled GDC-0214 (1 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35644155

Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 360 mg
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Subcutaneous risankizumab 180 mg
Number of subjects: 542

Group type: COMPARATOR
Intervention: Withdrawal (subcutaneous placebo)
Number of subjects: 542
Study: 32420624

Group type: EXPERIMENTAL
Intervention: Initial experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial control treatment
Number of subjects: 0
Study: 33820412

Group type: EXPERIMENTAL
Intervention: DistrACTION® Cards (MMJ Labs)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study: 34384459

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I), delivered in-person or via telehealth, five weekly sessions.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 62
Study: 33560210

Group type: EXPERIMENTAL
Intervention: Level 3 portable sleep study device
Number of subjects: 107

Group type: COMPARATOR
Intervention: In-laboratory polysomnography
Number of subjects: 107
Study: 36073088

Group type: EXPERIMENTAL
Intervention: Yoga and aerobic exercise
Number of subjects: 12
Study: 33173114

Group type: EXPERIMENTAL
Intervention: Slow induction group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fast induction group
Number of subjects: 18
Study: 33836459

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Moderate Continuous Exercise (MCT)
Number of subjects: 130
Study: 32164442

Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching with Phonological Emphasis (EMT + PE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Business as usual comparison condition
Number of subjects: 30
Study: 34467531

Group type: EXPERIMENTAL
Intervention: Karman aspiration cannula
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 40
Study: 34153968

Group type: EXPERIMENTAL
Intervention: Low-dose alteplase (0.6 mg/kg)
Number of subjects: 4551

Group type: COMPARATOR
Intervention: Standard-dose alteplase (0.9 mg/kg)
Number of subjects: 4551

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target SBP 130-140 mm Hg)
Number of subjects: 4551

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure management (<180 mm Hg)
Number of subjects: 4551
Study: 34044689

Group type: EXPERIMENTAL
Intervention: Differential settings (4.5‐µm spot and track spacing in cap interface and 4.2 µm in lenticule interface)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard settings (4.5‐µm spot and track spacing in cap and lenticule interface)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Differential settings
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard settings
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 32122834

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% diluted with dextrose 5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine 2% diluted with normal saline
Number of subjects: 60
Study: 35656654

Group type: EXPERIMENTAL
Intervention: LLLT of 660 nm
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: LLLT of 810 nm
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of wavelengths 660 and 810 nm
Number of subjects: 80

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study: 33639904

Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Therapy)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Factors associated with higher rates of stops/starts
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Factors associated with lower rates of stops/starts
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Factors associated with longer durations of sustained ART
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Factors associated with shorter durations of sustained ART
Number of subjects: 512
Study: 34979252

Group type: EXPERIMENTAL
Intervention: 1.5 g of TXA intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Number of subjects: 96

Group type: COMPARATOR
Intervention: 100 mL of normal saline intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Number of subjects: 96
Study: 33484658

Group type: EXPERIMENTAL
Intervention: School-based humanistic counselling (SBHC) plus pastoral care as usual (PCAU)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Pastoral care as usual (PCAU)
Number of subjects: 329